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Abstract
Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 (EBP50) is a phosphorylatable PDZ domain-containing adaptor
protein that is abundantly expressed in epithelium but was not yet studied in the endothelium. We report unusual nuclear
localization of EBP50 in bovine pulmonary artery endothelial cells (BPAEC). Immunofluorescent staining and cellular
fractionation demonstrated that EBP50 is present in the nuclear and perinuclear region in interphase cells. In the prophase
of mitosis EBP50 redistributes to the cytoplasmic region in a phosphorylation dependent manner and during mitosis EBP50
co-localizes with protein phosphatase 2A (PP2A). Furthermore, in vitro wound healing of BPAEC expressing phospho-mimic
mutant of EBP50 was accelerated indicating that EBP50 is involved in the regulation of the cell division. Cell cycle
dependent specific interactions were detected between EBP50 and the subunits of PP2A (A, C, and Ba) with
immunoprecipitation and pull-down experiments. The interaction of EBP50 with the Ba containing form of PP2A suggests
that this holoenzyme of PP2A can be responsible for the dephosphorylation of EBP50 in cytokinesis. Moreover, the results
underline the significance of EBP50 in cell division via reversible phosphorylation of the protein with cyclin dependent
kinase and PP2A in normal cells.
Citation: Boratko´ A, Gergely P, Csortos C (2012) Cell Cycle Dependent Association of EBP50 with Protein Phosphatase 2A in Endothelial Cells. PLoS ONE 7(4):
e35595. doi:10.1371/journal.pone.0035595
Editor: Laszlo Buday, Hungarian Academy of Sciences, Hungary
Received December 2, 2011; Accepted March 19, 2012; Published April 16, 2012
Copyright:  2012 Boratko´ et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by CNK80709 (GP) from the Hungarian Science Research Fund (www.otka.hu) and the TA´MOP 4.2.1./B-09/1/KONV-2010-0007
project implemented through the New Hungary Development Plan, co-financed by the European Social Fund. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: csortos@med.unideb.hu
Introduction
Ezrin-radixin-moesin (ERM) binding phosphoprotein of 50 kD
(EBP50) is a member of the Na+/H+ exchanger regulatory factor
(NHERF) family which consists of four related PDZ (postsynaptic
density 95/discs-large/zona occludens-1) domain containing
scaffolding proteins termed as NHERF1/EBP50, NHERF2/
E3KARP, NHERF3/PDZK1, and NHERF4/IKEPP [1].
NHERF1 was originally recognized as Na+/H+ exchanger-3
binding partner [2], and it has later been identified as an ERM
binding phosphoprotein [3]. NHERFs are highly abundant in the
epithelium and their role in Na+/H+ exchanger-3 regulation is
well established [4], therefore EBP50 was characterized mainly in
polarized epithelial cells up to the present.
EBP50 has two PDZ domains and a C-terminal ERM-binding
domain. It is believed that through these domains EBP50 forms
bridges among plasma-membrane and cytoskeleton proteins. Its
function, for example, in microvillar assembly as part of the
PDZK1/NHERF3-EBP50-ezrin complex was studied in details
[5]. It seems that EBP50 binds ezrin specifically in epithelial cells
and there is an interdependence of EBP50 and ezrin for their
apical localization [6,7]. However, recent paper describes the
effect of EBP50-moesin interaction in the contractile response of
artery [8]. Most of the interacting proteins bind to the first PDZ
domain, only a few partners relate with the second PDZ, like beta-
catenin [9]. Self association of EBP50 through the PDZ domains
[10], and the intramolecular interactions of EBP50 between the
PDZ2 and C-terminal domains result in an autoinhibition of
complex formation [11]. Protein-protein interactions between the
members of the NHERF family [5,12] have been described, as
well.
EBP50 is a subject to phosphorylation by several kinases and
these modifications have been suggested to alter its binding
activity. Oligomerization of EBP50 was shown to be regulated via
site-specific phosphorylation. Phosphorylation by PKC on Ser337/
Ser338 enhances the oligomerization [13]; and G protein-coupled
receptor kinase 6 was identified as the kinase responsible for
constitutive phosphorylation of Ser289 which facilitates PDZ
domain mediated interactions [12,14]. During mitosis EBP50 is
phosphorylated on Ser279 and Ser301 by the cyclin dependent
kinase 1 (Cdk1) and that phosphorylation inhibits its oligomeri-
zation, but allows association with Pin1, a peptidylprolyl isomerase
[15]. In addition, it was shown by S77A and S77D substitutions
that phosphorylation of the PDZ1 domain attenuates co-
localization of EBP50 with the cortical actin [16]. In agreement
with the outcome of phosphorylation on oligomerization, it was
demonstrated that PKC activation and EBP50 phosphorylation
promotes microvili rearrangement [17]. Recent study also showed
that phosphorylation of EBP50 by PKC within the PDZ2 domain
reduced its association with the cystic fibrosis transmembrane
conductance regulator [18]. On the other hand, phosphorylation
of EBP50 by Cdk1 inhibits its role in microvili formation in
interphase but not in mitotic cells [17].
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Dephosphorylation of the above mentioned sites is an equally
important element of the reversible phosphorylation, however,
phosphatases specific for EBP50 have not been identified yet.
Protein phosphatase 1 (PP1), 2A (PP2A), and 2B (PP2B) are the
major classes of serine/threonine specific protein phosphatases,
each having a heterodimer or –trimer holoenzyme form of one of
the catalytic subunits and one or two of the large number of the
variable regulatory subunits [19].
The aim of the present work was to characterize localization,
phosphorylation/dephosphorylation of the ERM binding phos-
phoprotein, EBP50, in bovine pulmonary artery endothelial cells
(BPAEC). We found mainly nuclear localization of EBP50 in
interphase cells, and its redistribution to the cytoplasm during the
course of mitosis parallel with its phosphorylation. PP2A was
identified as an interacting protein of EBP50 during pro-,
prometa-, meta-, ana-, telophase, and early cytokinesis supporting
that PP2A is responsible for the dephosphorylation of the Cdk1
phosphorylation sites.
Results
Nuclear localization of EBP50 in endothelial cells
To study subcellular localization of EBP50 in endothelial cells
(EC), we co-stained BPAEC with anti-EBP50 and anti-b-tubulin
antibody. By confocal microscopy EBP50 was detected mainly in
the nucleus and in the perinuclear region (Fig. 1A.a–c and Fig. S1,
parallel experiments using two different anti- EBP50 antibodies).
In a parallel experiment we also found EBP50 in the nuclei of
HUVEC (Fig. 1A.d–f), but in the cytoplasm of MCF7 human
breast adenocarcinoma cell line (Fig. 1A.j–l). Because EBP50
shares high sequence homology with NHERF2, to exclude the
possibility of cross-reaction of the EBP50-specific antibody with
NHERF2, we stained BPAEC with NHERF2 specific antibody as
well. Our result clearly shows that NHERF2 localizes in the
cytoplasm but not in the nucleus (Fig. 1A.g–i).
To ensure this rather unique nuclear appearance of EBP50 in
EC we cloned bovine EBP50 into a pCMV-Myc plasmid and
transfected the construct into endothelial and epithelial cells.
Immunofluorescent staining with tag specific antibody showed the
same result as above, namely, the recombinant EBP50 was in the
nuclear and perinuclear region in EC (Fig. 1A.m–o), however, it
was present in the cytoplasm of the epithelial cells (Fig. 1A.p–r).
To further strengthen our observation subcellular fractionations
of BPAEC and MCF7 were performed. Western blot analysis of
the fractions proved that EBP50 is present in the nuclear fraction
only in the endothelial cells. The purity of fractions was confirmed
using anti-b-tubulin antibody as a cytoplasmic and anti-lamin A/
C antibody as a nuclear marker (Fig. 1B). Moreover, the nuclear
appearance of EBP50 in endothelial cells was detected by
immunohistochemical study (Fig. S2).
Phosphorylation dependent localization of EBP50
Although the nuclear appearance of EBP50 was quite uniform
for the EC monolayer studied, we also observed that EBP50 left
the nuclear region in dividing cells. To identify the time-point of
re-localization we co-stained BPAEC with anti-EBP50 and anti-b-
tubulin antibodies, and DAPI. EBP50 was in the nucleus in
interphase cells, however, during prophase its redistribution to the
cytoplasm was apparent and we could detect its disappearance
from the cytosol only in the phase of cytokinesis (Fig. 2).
Cdk1 catalyzed phosphorylation and mobility-shift upon SDS-
PAGE of EBP50 in mitotic cells were described in HeLa cells [15].
Therefore, we hypothesized that the varying localization of the
protein during the course of mitosis can be related to its
phosphorylation state. To prove our hypothesis first a phospho-
mimic construct of EBP50 was created by mutation of Ser288 and
Ser310 side-chains, which were known to be phosphorylated in
mitotic cells by Cdk1 [15], to Asp to imitate phosphorylation. On
SDS-PAGE the apparent size of EBP50 mutant shifted upward
compared to the recombinant wild type EBP50 (Fig. 3A). Next we
confirmed by immunofluorescent staining that the phospho-mimic
mutant form of EBP50 showed cytoplasmic allocation but the
wild-type recombinant protein was in the nucleus (Fig. 3B).
To verify the phosphorylation of the endogenous EBP50 we
synchronized BPAEC. Cells were arrested in G1/S using double
thymidine block, and G2/M phase arrest was established using
nocodazole treatment. EBP50 was detected as a 55 kD band in the
lysate of asynchronized cells, however, we observed an additional
pale band at higher molecular mass that completely disappeared in
the lysate of cells in G1/S. Conversely, the band of higher mass
had a massive manifestation 8 h after releasing the cells from the
thymidine block, as the majority of cells got near to the phase of
mitosis (Fig. 3C). Based on the previously published data [15] and
our results (Fig. 3A–B) this higher molecular mass band could be
the phosphorylated form of EBP50. Furthermore, these observa-
tions proved our hypothesis that the relocalization of EBP50
occurs in a phosphorylation-dependent manner.
Phospho-mimic EBP50 supports wound healing
As proliferation/cell division and migration are essential in
wound healing [20,21], to further demonstrate the significance of
the phosphorylation of EBP50 during the cell cycle, we compared
the timing of wound healing of mock-transfected BPAEC
monolayer with the ones overexpressing wild type- or phospho-
mimic EBP50 using electric cell impedance measurements, ECIS
(Fig. 4). The time from the beginning of wound healing to the time
at 50% of the maximum impedance (effective time) was about the
same for the mock-transfected control (1.9 h) and the sample
overexpressing the wild type EBP50 (1.8 h). However, the
phopho-mimic mutant form of EBP50 significantly accelerated
the healing process (effective time= 1.5 h).
EBP50 associates with PP2A-Ba holoenzyme
As protein phosphorylation/dephosphorylation is a reversible
process, next we intended to identify the protein phosphatase
catalyzing the dephosphorylation of EBP50. First BPAEC were
arrested in mitotic phase and at the point of the release the media
were implemented with specific protein phosphatase inhibitors.
Okadaic acid of 5 nM was able to maintain the phosphorylation
state of EBP50 for 6 h after the release suggesting that PP2A is
involved in the dephosphorylation. Furthermore, 2 nM calyculin
A, a specific inhibitor of PP1, had no effect on the above
dephosphorylation process (unpublished data).
Subsequently, we examined whether protein-protein interac-
tions could be detected between EBP50 and PP2A or PP1. Lysates
from thymidine or nocodazole treated cells were prepared and the
endogenous EBP50 was immunoprecipitated from each lysate
using anti-EBP50 antibody. The immunoprecipitated complexes
were probed in Western blot with antibodies raised against
different protein phosphatase subunits. As shown in Figure 5A,
EBP50 co-immunoprecipitated with the A (PP2Aa) and C (PP2Ac)
subunits of PP2A, but no interaction of EBP50 was detected with
PP1c a and d isoforms. EBP50 was also observed in PP2Ac
immunoprecipitates of lysates with thymidine or nocodazole
treatments. The interaction between EBP50 and PP2A was clearly
more pronounced in lysates of mitotic phase cells (Fig. 5B).
Since the apparent size of the B subunits (about 55 kD) is close
the size of IgG we could not detect co-immunoprecipitation of the
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B subunits with EBP50. To identify the third, variable B subunit of
PP2A - which determine the substrate specificity and subcellular
localization of the holoenzyme – GST-tagged bacterial expression
construct of EBP50 was created. Immobilized recombinant EBP50
or GST protein, as a negative control, were incubated with or
without BPAEC lysates in pull down experiments. The total cell
lysates and the eluted proteins were analyzed by Coomassie
staining (Fig. 6A) and by Western blot (Fig. 6B) using antibodies
for different PP2A subunits. The Coomassie staining shows the
efficiency of the purification from the bacterial extract. The results
of the Western blot indicate the presence of B subunit in the GST-
EBP50 pull-down along with A and C subunits of PP2A (Fig. 6B).
In the same set of experiment B9 subunit of PP2A was not
detectable.
We were able to confirm the specific interaction between EBP50
and PP2A Ba subunit using overexpressed B subunits with Anti-
V5 Affinity Gel. BPAEC were transfected with expression
contructs containing the coding sequence of PP2A Ba or B9c
subunits and the overexpressed proteins were bound to the anti-
V5 antibody immobilized on the resin. The eluted recombinants
and the presence of EBP50 in the eluted fractions were analyzed
by Western blot (Fig. 6C). Although the amount of Ba and B9c
subunits appears the same (lower panel), the binding of
endogenous EBP50 was detectable only to Ba. Taken together,
data of immunoprecipitations demonstrate that endogenous
EBP50 and endogenous PP2A physically associate, moreover,
our results indicate that EBP50 interacts with the holoenzyme
form of PP2A containing Ba.
The mitotic phase interaction led us to search possible co-
localization of EBP50 with PP2A during mitosis. Therefore,
BPAEC were co-stained with anti-EBP50 and anti-PP2Ac
antibodies (Fig. 7A). While EBP50 has nuclear and perinuclear
distribution in interphase cells, PP2Ac appears to be present
mainly in the cytoplasm, consequently, merge of parallel images
emphasizes no overlap of staining. However, in agreement with
our immunoprecipitation experiments which indicated strong
protein-protein interaction between EBP50 and PP2A, we
detected co-localization of EBP50 and PP2Ac in pro-, prometa-,
meta-, ana-, and telophase. We also observed that the two proteins
still co-localize at the beginning of cytokinesis, when EBP50
showed cytoplasmic appearance. On the other hand, no co-
localization could be observed in the late cytokinesis. To quantify
the extent of association the Pearson’s correlation coefficient was
determined at the different phases of the cell cycle. Positive value
Figure 1. Nuclear localization of EBP50 in BPAEC. A) Immunofluorescence staining of confluent BPAEC (a–c,g–i), HUVEC (d–f), MCF7 (j–l) and
pCMV-myc EBP50 transfected BPAEC (m–o), and HeLa (p–r) cells was performed using anti-EBP50 (anti-SLC9A3R1 antibody, Abgent) (a,j: red, d: green),
anti-tubulin (b,k: green), anti-NHERF2 (g: green), and monoclonal anti-c-myc (m,p: green) primary antibodies. Actin microfilaments were stained with
Texas Red conjugated phalloidin (e,h, n,q: red). c,f,i,l,o and r are merged images of a–b, d–e, g–h, j–k, m–n, and p–q, respectively. Representative data
of at least three independent experiments are shown. Scale bars: 100 mm. B) Cellular fractionations of BPAE and MCF7 cells were made as described in
Materials and Methods. The fractions were analyzed with anti-EBP50 (anti-SLC9A3R1 antibody Abgent), anti-b-tubulin as a cytoplasmic and anti-lamin
A/C antibodies as a nuclear marker. CL: cell lysate, CP1: cytoplasmic fraction 1, CP2: cytoplasmic fraction 2, N: nuclear fraction.
doi:10.1371/journal.pone.0035595.g001
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of the coefficient indicates co-localization/association of the
studied proteins. Significant co-localization was found from the
prophase till the early cytokinesis, but not in late cytokinesis,
compared to interphase (Fig. 7B).
To confirm that the EBP50-PP2A interaction is specific and
phosphorylation dependent, the same analysis of cells co-stained
with PP2Ac and NHERF2 specific primary antibodies was
performed. NHERF2 has the highest amino acid sequence
homology with EBP50 in the NHERF family, but NHERF2 does
not exhibit possible Cdk1 phosphorylation sites. Although both
PP2Ac and NHERF2 are in the cytoplasm of interphase cells,
neither co-localization nor interaction between these proteins in
any phase of the observed cells could be detected (Fig. 7C).
Discussion
EBP50 is a well characterized protein in epithelium, yet little is
known about its function in other cell types. It is expressed at high
levels in the kidney, liver, small intestine, and placenta, but also
expressed at lower levels in the brain and lung [2,3]. Based on
studies of epithelial cells where EBP50 is localized to the plasma
membrane and the cytoplasm, it is accepted that its primary
function is to act as a scaffold protein linking transmembrane
proteins to various cytoskeletal proteins. In polarized cells such as
kidney proximal tubule cells it is localized primarily in the apical
region [22] where its association with proteins like cystic fibrosis
transmembrane conductance regulator, podocalyxin, G-protein
coupled- or tyrosine kinase receptors was found [23,24,25].
In interphase BPAEC and HUVEC we detected EBP50 in the
nucleus and in the perinuclear region in contrast with the above
mentioned cytoplasmic location found by others in epithelial cells.
Our observation was verified by immunfluorescent staining, cell
fractionation, and recombinant protein expression. The amino
acid sequence deduced from the DNA coding the endothelial
EBP50 (SLC9A3R1) is identical with the published bovine
sequence in the database (NM_001077852). Therefore the varying
location of EBP50 in endothelial and epithelial cells may be the
consequence of different interactive protein partners suggesting
different function of EBP50 in the two cell types. We also
compared the localization of EBP50 and NHERF2 in BPAEC, as
these proteins are the most similar members of the NHERF family
(49% amino acid identity). Results of immunoflurescence clearly
excluded the possibility of non-specific binding of the primary
antibodies; EBP50 and NHERF2 appeared at different locations
in BPAEC. In addition, we detected the same pattern of
localization of the recombinant EBP50, as well. Only a few
studies [26,27] have reported nuclear localization of EBP50 but
only in cancer cell lines not in normal cells. It was shown that
EBP50 is overexpressed in hepatocellular carcinoma cell lines and
it is localized in the cytoplasm and in the nucleus [9]. In addition,
cell cycle dependent shuttling between the nucleus and the
cytoplasm of merlin, an ERM-like tumor suppressor protein, was
described [28] in glioma and osteosarcoma cells. Interestingly,
others [29] also detected ERM proteins in the nucleus of MDCK
and HeLa cells.
It is known that EBP50 can be phoshorylated by protein kinases
on multiple sites. It is phosphorylated during mitosis by Cdk1 at
Ser279 and Ser301 and this phosphorylation inhibits its oligomer-
ization [15]. The SPX(K/R) preferred phosphorylation motifs of
Cdk1 are conserved in EBP50 of different species, thus Ser279 and
Ser301 residues in the rabbit protein referred in [15] correspond to
Ser288 and Ser310 in the bovine EBP50. Therefore we concluded
Figure 2. Localization of EBP50 during the phases of the cell cycle. Immunofluorescence staining of BPAE cells was performed using anti-
EBP50 (red) primary antibody (anti-SLC9A3R1 antibody, Abgent). Phases of the cell cycle were identified by tubulin (green) and DAPI (blue) staining.
Representative images from five independent experiments are shown. Scale bar: 100 mm.
doi:10.1371/journal.pone.0035595.g002
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that the cell cycle dependent localization change and mobility shift
on SDS-PAGE of the endothelial EBP50 we observed are in
parallel with the phosphorylation and possibly the oligomerization
state of the protein. Furthermore, phosphorylation of EBP50 by
the employment of its phospho-mimic mutant (S288D:S310D)
form showed mobility shift on SDS-PAGE and cytoplasmic
localization as did the endogenous EBP50 in dividing cells.
The nuclear envelope offers a selective barrier between the
nuclear compartment and the cytoplasm. At the transition from
prophase to prometaphase of mitosis the breakdown of the nuclear
envelope leads to combination of the two compartments [30].
However, we could detect EBP50 in the cytoplasm in cells in early
prophase to late cytokinesis, suggesting an active transporting
mechanism. A number of proteins required for nucleocytoplasmic
transport have important functions during mitosis [31], still the
significance of the varying location of EBP50 is not clear yet.
Recent studies showed that phosphorylation, one of the major
posttranslational modifications, strongly regulates the interaction
of EBP50 with several proteins, like moesin and ezrin [8,17].
Further investigations are necessary to clarify what is the
function(s) of EBP50 in the nucleus and cytoplasm and what are
the targeted proteins in these compartments.
The physiological significance of the phosphorylation of EBP50
was observed in wound healing as we found that the phospho-
mimic mutant (S288D:S310D) form of EBP50 significantly
accelerated the wound healing of BPAEC. In vascular smooth
muscle cells siRNA mediated depletion of EBP50 increased cell
Figure 3. Localization of EBP50 is phosphorylation-dependent
in BPAEC. pCMV-Myc EBP50 wild type (wtEBP50) and pCMV-Myc
EBP50 S288D:S310D phosphomimic mutant (muEBP50) proteins were
analysed by Western blot (A) and immunofluorescence (B). Anti-myc
(green) antibody was used for labeling of wild type and mutant EBP50
both in Western blot and immunofluorescent experiments. Actin
microfilaments were stained with Texas Red conjugated phalloidin
(red) and DAPI (blue) staining was used to visualize the nuclei. Scale bar:
100 mm. Panel C: Phosphorylation level of EBP50 in synchronized BPAE
cells. Cells were arrested in G1/S phase using double thymidine block
and in mitotic phase by nocodazole treatment as described in Materials
and Methods. Samples of asynchronized cells (AS), 1st and 2nd
thymidine block cells (G1/S), and cells after 3 or 8 h release of the
thymidine block without or with addition of 80 ng/ml nocodazole (ND)
were tested for EBP50 (anti-NHERF1(A310) antibody, Cell Signaling
Technology) by Western blot. Representative images from at least three
independent experiments are shown.
doi:10.1371/journal.pone.0035595.g003
Figure 4. Phospho-mimic EBP50 supports wound healing.
BPAEC were transfected with pCMV-Myc EBP50 wild type (wt EBP50)
and pCMV-Myc EBP50 S288D:S310D phosphomimic mutant (mu EBP50)
and were plated onto two 8W10E arrays 24 h post-transfection. After
cells achieved monolayer density (about 1000 V impedance) an
alternate current of 5 mA at 60 kHz frequency was applied for 30 sec
duration to establish wounds in the cell layer (0 h); after that the
impedance was measured for 5 h. The average results from three
independent experiments each made with two or three parallel
measurements are shown. Error bars represent SD.
doi:10.1371/journal.pone.0035595.g004
Figure 5. PP2A subunits associate with cellular EBP50. EBP50
(panel A) or PP2A C subunit (panel B) was immunoprecipitated from
lysates of thymidine or nocodazole treated BPAEC as described in
Materials and Methods. The IP complexes were probed for PP2Aa,
PP2Ac, and PP1c (a and d) (A) or EBP50 (anti-NHERF1(A310) antibody,
Cell Signaling Technology) and PP2Ac subunit (B). Ø: cell lysate without
immunoprecipitation, AS: asynchonized cell lysate, S: early S phase cell
lysate, M: mitotic phase lysate. Additional bands at 55 kD are IgG.
Representative blots from three independent experiments are shown.
doi:10.1371/journal.pone.0035595.g005
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migration and induced cell morphology changes, moreover,
binucleated cells were observed indicating the defect of cytokinesis
[32]. NHERF1/EBP50 gene mutations were identified in cancer
cells [33], in addition knockdown of EBP50 increased cellular
proliferation and migration of cancer cell lines suggesting that
EBP50 acts as a tumor suppressor [34]. Our findings in normal
cells underline the importance of EBP50 in cell division via the
cyclin dependent kinase phosphorylation and PP2A dependent
dephosphorylation of the protein.
Based on experiments with the aid of phosphatase inhibitors, it
was suggested that the dephosphorylation of the Cdk1 (mitosis) -
specific phosphoserine side chains in HeLa cells is mediated by
PP1 or PP2A phosphatases, but not by PP2B [15]. Our attempts to
verify the involvement of PP1 in the dephosphorylation of EBP50
in BPAEC have failed, since specific inhibitor (calyculin A, 2 nM)
of PP1 had no effect on the phosphorylation state of EBP50
arrested in G2/M phase, moreover, immunoprecipitation exper-
iments did not show protein-protein interaction between EBP50
and PP1. On the other hand, our results indicated that PP2A
interacts and co-localizes with EBP50 in a cell cycle dependent
manner. The holoenzyme form of PP2A is a heterotrimer that
consists of a core dimer, composed of a scaffold (A) and a catalytic
(C) subunit that associates with a variety of regulatory subunits
(generally named B subunit) [19]. We did detect remarkable
amount of A and C subunits in the immunoprecipitate of EBP50
and definite co-localization of the C subunit and EBP50 in the
mitotic phase BPAEC. Furthermore, we identified Ba (also named
as PR55) [19] with pull-down assays as the third subunit in the
PP2A holoenzyme interacting with EBP50.
No PDZ domain was identified in the PP2A subunits and our
results do not specify which subunit(s) of the PP2A heterotrimer is/
are directly interacting with EBP50. A C-terminal motif was
described in several peptides and proteins, which was shown to be
responsible for binding to the PDZ domains in EBP50 [23,35]. We
compared the sequence of the four amino acids at the C-terminal
of the PP2A subunits (LSLA for A, DYFL for C and DKVN for
Ba subunit) with this DS/TxL motif. Although none of these
tetrapeptides seem to be optimal, still we cannot exclude any
subunit of PP2A as a potential binding partner for EBP50, as the
results of others [23,35] with peptide bonding indicate broad
variations in the sequence.
The location change and the co-localization of EBP50 with
PP2Ac during the course of mitosis were parallel, with the highest
levels of co-localization during the phases from metaphase to early
cytokinesis. We also observed that the ratio of dividing cells was
higher in cells expressing the phospho-mimic mutant
(S288D:S310D) compared to those expressing the wild type
EBP50. Since we could not detect the phosphorylated form of
EBP50 in the lysate of interphase cells, these results suggests that
the dephosphorylation of P-Ser288 and P-Ser310 is necessary for the
mitotic exit and it is catalyzed by PP2A. Dephosphorylation of the
Cdk1 substrates by PP1 and PP2A as an element of the exit from
mitosis in vertebrate cells was described earlier [36,37,38].
Our results show that a protein thought to be a linker between
the plasma membrane and cytoplasmic/cytoskeletal proteins may
be involved in nuclear events as well. We provide evidences for cell
cycle dependent localization and phosphorylation of EBP50, and
its interaction with PP2A during mitosis. Our results indicate that
EBP50 may have a significant role in the course of the cell cycle
and that PP2A can be the phosphatase dephosphorylating P-Ser288
and P-Ser310 of EBP50 in BPAEC.
Figure 6. Ba subunit of PP2A interacts with EBP50. Panels A and
B: Bacterially expressed glutathione S-transferase (GST) and GST-tagged
wild-type EBP50 were loaded onto glutathione-Sepharose as described
in Materials and Methods. After a washing step the resin samples were
incubated with BPAEC lysate or cell lysis buffer. Non-binding proteins
were washed out and the bound proteins were eluted with 10 mM
glutathion. Coomassie staining (A) and Western blot probed with PP2A
A, B, B9, or C specific antibodies (B) of the bacterial and endothelial cell
lysates (Total) and the eluted fractions after the pull-down are shown.
Panel C: BPAEC monolayers were transfected with pcDNA3.1 V5-His
(vector ctr), pcDNA3.1 V5-His PP2A Ba (PP2A Ba–V5) and pcDNA3.1 V5-
His B9c (PP2A B9c–V5) plasmids. Lysates of the transfected cells were
incubated with Anti-V5 Agarose Affinity Gel as described in Materials
and Methods, and the bound proteins were eluted by boiling the resin
in 16 SDS sample buffer. Western blot analysis of the lysates of
transfected cells (Total) and eluted samples were done using EBP50
(upper panel) and V5-tag (lower panel) specific antibodies. Additional
bands at 55 kD are IgG. Representative data of three independent
experiments are shown.
doi:10.1371/journal.pone.0035595.g006
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Materials and Methods
Materials were obtained from the following sources: thymidine,
nocodazole paraformaldehyde, dimethylsulfoxide, bovine serum
albumin, Anti-V5 Agarose Affinity Gel antibody produced in
mouse: Sigma (St Louis, MO); anti-PP1 catalytic subunit antibody:
R&D System (Minneapolis, MN); anti-SLC9A3R1 antibody:
Abgent (San Diego, CA); anti-PP2A B subunit (most specific for
Ba) and anti-NHERF1(A310) antibodies, anti-rabbit IgG HRP-
linked and anti-mouse IgG HRP-linked secondary antibodies: Cell
Signaling Technology, Inc. (Beverly, MA); anti-PP2A B9 subunit,
monoclonal anti-PP2Ac, monoclonal anti-b-tubulin antibodies:
Upstate Biotechnology (Lake Placid, NY); anti-NHERF2 (C-2),
anti-lamin A/C (H-110) antibodies: Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA); monoclonal anti-c-myc antibody: Zymed
Laboratories (South San Francisco, CA); Protease Inhibitor
Cocktail Set III EMD Biosciences (San Diego, CA); Alexa 488-,
Alexa 546-conjugated secondary antibodies, Texas Red-phalloidin
and ProLong Gold Antifade medium with DAPI: Molecular
Probes (Eugene, OR), FuGENEH HD Transfection Reagent:
Roche (South San Francisco, CA); pCMV-Myc and pcDNA3.1
V5-His vector: Clontech Laboratories, Inc. (Mountain View, CA);
restriction enzymes, T4 DNA ligase, PhusionH High-Fidelity DNA
Polymerase: Thermo Scientific, Inc. (Vantaa, Finland).
Substances for cell culturing were from Invitrogen Corporation
(Carlsbad, CA). All other chemicals were obtained from Sigma (St
Louis, MO).
Cell cultures, cell synchronization, transfection
Bovine pulmonary artery endothelial cells (BPAEC) (culture
line-CCL 209) were obtained frozen at passage 8 (American Type
Tissue Culture Collection, Rockville, MD), and were utilized at
passages 17–22. MCF7 (catalogue No: 86012803) cells were
obtained frozen at passage 11 (European Collection of Cell
Cultures, Salisbury, UK). Cells were maintained at 37uC in a
humidified atmosphere of 5% CO2 and 95% air in MEM
supplemented with 10% (v/v) fetal bovine serum (heat inactivat-
ed), 1% sodium pyruvate, 0.1 mM MEM non-essential amino
acids solution. HeLa cells (catalogue No: 93021013) were obtained
frozen at passage 4 (ECACC) and maintained in DMEM
supplemented with 10% (v/v) FBS, 2 mM glutamine and
0.1 mM non-essential amino acids solution.
BPAEC were synchronized at G1/S phase using double
thymidine block as follows. Cells were treated with 2 mM
thymidine for 16 h. After this first thymidine block cells were
Figure 7. Co-localization of EBP50 and PP2Ac during mitosis in BPAEC. (A) Immunofluorescence staining of BPAEC was performed using
anti-EBP50 (anti-SLC9A3R1 antibody, Abgent) (red) and anti-PP2Ac (green) primary antibodies. Phases of the cell cycle were identified using DAPI
staining (not shown). Scale bars: 100 mm. Co-localization of EBP50 (B) or NHERF2 (C) and PP2Ac was evaluated by determination of Pearson cross-
correlation coefficient. The results are presented as means 6 SD from 50–100 (B) or 25–30 (C) independent cells for each studied phase of the cell
cycle. Statistical analysis was done with ANOVA on ranks. Significant changes compared to the interphase cells are indicated by * (P,0.05). I:
interphase, P: prophase, PM: prometaphase, M: metaphase, A: anaphase, T: telophase, C: cytokinesis, LC: late cytokinesis.
doi:10.1371/journal.pone.0035595.g007
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released for 8 h and then treated with 2 mM thymidine for 16 h
again. G2/M phase cells were obtained by 14–16 h treatment
with 80 ng/ml nocodazole.
To express recombinant proteins 1 mg total DNA/3 ml
FuGENEH HD reagent was mixed and added to the culture
plates containing cells at ,80% confluency according to the
manufacturer’s instruction. Cells were analyzed 24 h later.
Cloning of EBP50
Total RNA was extracted from BPAEC using ZR RNA
MicroPrepTM (Zymo Research Corporation, CA). cDNA was
synthesized from 2 mg of total RNA using oligo-dT primer and M-
MLV reverse transcriptase (Promega Corporation, USA). The
coding region of wild-type EBP50 was amplified by PCR using the
following primers (based on the sequence of SLC9A3R1,
NM_001077852) containing XhoI and NotI restriction sites for
subcloning: 59-GCCTCGAGTTATGAGCGCGGACGCGG-39
(forward) and 59-ATATGCGGCCGCTCAGAGGTTGCTGAA-
GAGTTC-39 (reverse). The primers were synthesized by Inte-
grated DNA Technologies (Coralville, IA). EBP50 S288D:S310D
mutant was created using oligonucleotides with the necessary
mutant sequence. PCR products and pCMV-Myc vector were
double digested with XhoI and NotI and ligated using 1:3
vector:insert molar ratio. The DNA sequences of the constructs
were confirmed by sequencing (Clinical Genomics Center,
MHSC, RCMM, University of Debrecen). One nucleotide
deviance was detected (at position 192) that did not cause amino
acid change.
Immunofluorescence and microscopy
Cells were plated onto 0.2% gelatin coated glass coverslips and
grown, washed once with 16PBS (137 mM NaCl, 2.7 mM KCl,
4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4) and fixed with
3.7% paraformaldehyde in 16 PBS for 15 min at room
temperature. Between each step, the cells were rinsed three times
with 16PBS. The cells were permeabilized with 0.5% Triton X-
100 in PBS at room temperature for 15 min, blocked with 2%
BSA in PBS for 30 min at room temperature, and incubated with
primary then with secondary antibodies diluted in blocking
solution for 1 h at room temperature. Cover slips were rinsed
and mounted in ProLong Gold Antifade medium.
Images were acquired with a Carl Zeiss Axioskope-20
microscope using Zeiss Plan-NEC FLUAR 6361.25 NA oil
immersion objective and Axiocam color camera (Zeiss, model 412-
312). Confocal images were acquired with an Olympus Fluoview
FV1000 confocal microscope using UPLSAPO 6061.35 NA oil
immersion objective on an inverted microscope (Olympus IX81) at
25uC. Images were processed using FV10-ASW v1.5 software and
further processed with PhotoShop Imaging software.
Nonspecific binding of the secondary antibodies was checked in
control experiments (not shown).
Immunoprecipitation
BPAEC were grown in 100-mm tissue culture dishes and treated
with thymidine or nocodazole, rinsed three times with 16 PBS
and then collected and lysed with 600 ml of immunoprecipitation
(IP) buffer (20 mM Tris HCl, pH 7.4, 150 mM NaCl, 2 mM
EDTA, 2 mM sodium vanadate, 1% Nonidet P-40) containing
protease inhibitors. The lysate was centrifuged with 10,000 g for
15 min at 4uC. To avoid nonspecific binding, the supernatants
were precleared with 50 ml of protein G Sepharose (GE
Healthcare, Piscataway, NJ) at 4uC for 3 h with end-over-end
rotation. Protein G Sepharose was removed by centrifugation at
4uC for 10 min, and the supernatant was incubated with the
appropriate volume of antibody at 4uC for 1 h and then with 50 ml
of fresh protein G Sepharose at 4uC overnight with gentle rotation.
The resin was washed three times with 300 ml of IP buffer and
then resuspended in 150 ml of 16SDS sample buffer, boiled, and
microcentrifuged for 5 minutes. The supernatant was further
analyzed by Western blot.
Western blotting
Protein samples were separated by SDS-PAGE and transferred
to 0.45 mm pore sized Hybond ECL Nitrocellulose Membrane
(GE Healthcare, Piscataway, NJ). Western blots were imaged using
an Alpha Innotech FluorChemH FC2 Imager.
Subcellular fractionation
ProteoJETTM Cytoplasmic and Nuclear Protein Extraction Kit
(Fermentas) were used for subcellular fractionation. Cells were
collected in cell lysis buffer, containing 0.01 M DTT and protease
inhibitor, vortexed and kept on ice for 10 min. Cytoplasmic
fraction (CP1) was obtained by centrifugation at 500 g for 7 min
and further cleaned by centrifugation at 13 000 g for 15 min at
4uC (CP2). Nuclear protein fraction (N) was obtained after
washing the pellet from the first centrifugation two times with
Nuclei washing buffer. The efficiency of fractionation was
analyzed by immunoblotting using b-tubulin antibody as a
cytoplasmic and lamin A/C antibody as a nuclear marker.
GST pull-down assay
Escherichia coli BL21 (DE3) transformed with pGEX-4T-2
containing glutathione S-transferase (GST) or pGEX-4T-2
containing wild-type EBP50 coding DNA sequence fused with
GST were induced with 1 mM IPTG and grown at 37uC with
shaking for 3 h. Cells were harvested by centrifugation, sonicated
in lysis buffer (50 mM Tris-HCl (pH 7.5), 0.1% Tween 20, 0.2%
2-mercaptoethanol, protease inhibitors) and proteins were isolated
by affinity chromatography on glutathione Sepharose 4B (GE
Healthcare, Piscataway, NJ) according to the manufacturer’s
protocol. BPAEC grown in 100-mm culture flasks were washed
twice with 16 ice-cold PBS, scraped, and lysed in 600 ml lysis
buffer. The lysates were incubated with GST or GST-EBP50
fusion proteins coupled to glutathione Sepharose beads for 2 h at
4uC. The beads were washed three times with 16 PBS then the
GST fusion proteins were eluted with 10 mM glutathione and
were tested by SDS-PAGE and confirmed by Western blot.
Anti-V5 Agarose Affinity Gel
BPAEC grown in 6 well plates were transfected with pcDNA3.1
V5-His, pcDNA3.1 V5-His PP2A Ba, or pcDNA3.1 V5-His PP2A
B9c construct prepared in our laboratory. 24 h after transfection
the cells were washed twice with 16 ice-cold PBS, scraped, and
lysed in 600 ml lysis buffer (50 mM Tris-HCl (pH 7.5), 0.2% 2-
mercaptoethanol and protease inhibitors). The cell lysates were
sonicated then centrifuged at 10 000 g for 10 min at 4uC. The
supernatant was added to 50 ml Anti-V5 Agarose conjugate and
rotated for 5 h at 4uC. Beads were washed 3 times with PBS then
boiled with 16 SDS buffer and analyzed by Western blot.
In vitro wound healing assay
To study wound healing/cell migration ECIS (Electric cell-
substrate impedance sensing) model Zh, Applied BioPhysics Inc.
(Troy, NY) was used that applies high electric field to make a well
defined injury in a confluent cell monolayer and to screen the
repopulation of this wounded area by noninvasive measurements
[20,39]. Wild type, mock, or mutant EBP50 transfected cells were
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seeded on type 8W10E arrays. After the cells achieved monolayer
density (about 1000 V impedance), an alternate current of 5 mA
at 60 kHz frequency was applied for 30 sec duration to establish
wounds in the cell layer, which led to the death and detachment of
cells present on the small active electrode, then the impedance was
measured for 5 h. The impedance in each wounded well increased
gradually, until it reached a maximum plateau value.
Immunohistochemistry
Immunohistochemical staining on paraffin-embedded human
skin sections (5 mm) was performed as follows. Samples were
deparaffinized in xylene and rehydrated in decreasing concentra-
tions (100, 95 and 70%) of ethanol followed by a 10 min
incubation in PBS (pH 7.4). Sections were treated with 3%
hydrogen peroxide in methanol for 15 min to block endogenous
peroxidase activity and then rinsed briefly in PBS. Next the
samples were subjected to antigen retrieval by heating for 2 min in
a pressure cooker in 0.01 M sodium citrate buffer (pH 6.0).
Nonspecific binding was blocked by incubating the slides for
60 min in PBS containing 1% BSA. EBP50 antibody was applied
in a 1:50 dilution in blocking solution O/N at 4uC and the
negative control sections were incubated with blocking solution
O/N at 4uC. After extensive washing (three times for 2 min) with
PBS, samples were incubated with Alexa594 conjugated secondary
antibody for 2 hours at room temperature in dark. Samples were
rinsed for 5 min with PBS and mounted with ProLongH Gold
Antifade Reagent with DAPI. Pictures were taken with a Zeiss
Axioskope-20 microscope with 10061.3 NA oil immersed
objective.
Statistical analysis
Pearson correlation coefficient was determined as described in
[40]. Analysis of Variance on Ranks was performed on Pearson
coefficients using SigmaStat. Statistical significance was deter-
mined at P,0.05 by Dunn’s Method, multiple comparisons versus
control group (group of interphase cells).
Supporting Information
Figure S1 Nuclear localization of EBP50 in BPAEC.
Immunofluorescence staining of confluent BPAEC was performed
using anti-EBP50 (anti-NHERF1(A310) antibody, Cell Signaling
Technology) (a: green) anti- primary antibodies. Actin microfila-
ments were stained with Texas Red conjugated phalloidin (b: red).
c is merged image of a and b. Representative data of at least three
independent experiments are shown. Scale bars: 100 mm.
(TIF)
Figure S2 EBP50 is present in the nucleus of endothelial
cells in vivo. Immunofluorescent staining was performed on
human skin sections using anti-EBP50 (anti-SLC9A3R1 antibody,
Abgent) (c:red) primary antibody. Blood vessels were identified by
morphological aspects using light microscope (a, e). Nuclei were
stained with DAPI (b, f: blue). No non-specific binding of secondary
antibody was detected in control experiment (g). d and h are
merged images of b–c and f–g, respectively.
(TIF)
Acknowledgments
The authors are most thankful to Dr. Gyo¨rgy Vereb and Dr. Gyo¨rgy
Va´mosi for their help in the statistical analyses and confocal microscopy,
respectively. HUVEC was kindly provided by Zolta´n Vere´b. The authors
gratefully acknowledge the advice of Dr. La´szlo´ Vira´g with the evaluation
of immunohistochemistry experiments and the help of Mrs Erzse´bet
Herba´ly with processing histology samples.
Author Contributions
Conceived and designed the experiments: AB CC. Performed the
experiments: AB. Analyzed the data: AB CC. Contributed reagents/
materials/analysis tools: CC PG. Wrote the paper: AB PG CC.
References
1. Donowitz M, Cha B, Zachos NC, Brett CL, Sharma A, et al. (2005) NHERF
family and NHE3 regulation. J Physiol 567: 3–11.
2. Weinman EJ, Steplock D, Wang Y, Shenolikar S (1995) Characterization of a
protein cofactor that mediates protein kinase A regulation of the renal brush
border membrane Na(+)-H+ exchanger. J Clin Invest 95: 2143–2149.
3. Reczek D, Berryman M, Bretscher A (1997) Identification of EBP50: A PDZ-
containing phosphoprotein that associates with members of the ezrin-radixin-
moesin family. J Cell Biol 139: 169–179.
4. Weinman EJ, Steplock D, Tate K, Hall RA, Spurney RF, et al. (1998) Structure-
function of recombinant Na/H exchanger regulatory factor (NHE-RF). J Clin
Invest 101: 2199–2206.
5. LaLonde DP, Garbett D, Bretscher A (2010) A regulated complex of the
scaffolding proteins PDZK1 and EBP50 with ezrin contribute to microvillar
organization. Mol Biol Cell 21: 1519–1529.
6. Fievet B, Louvard D, Arpin M (2007) ERM proteins in epithelial cell
organization and functions. Biochim Biophys Acta 1773: 653–660.
7. Ingraffea J, Reczek D, Bretscher A (2002) Distinct cell type-specific expression of
scaffolding proteins EBP50 and E3KARP: EBP50 is generally expressed with
ezrin in specific epithelia, whereas E3KARP is not. Eur J Cell Biol 81: 61–68.
8. Baeyens N, Horman S, Vertommen D, Rider M, Morel N (2010) Identification
and functional implication of a Rho kinase-dependent moesin-EBP50 interac-
tion in noradrenaline-stimulated artery. Am J Physiol Cell Physiol 299:
C1530–1540.
9. Shibata T, Chuma M, Kokubu A, Sakamoto N, Hirohashi S (2003) EBP50, a
beta-catenin-associating protein, enhances Wnt signaling and is over-expressed
in hepatocellular carcinoma. Hepatology 38: 178–186.
10. Fouassier L, Yun CC, Fitz JG, Doctor RB (2000) Evidence for ezrin-radixin-
moesin-binding phosphoprotein 50 (EBP50) self-association through PDZ-PDZ
interactions. J Biol Chem 275: 25039–25045.
11. Bhattacharya S, Dai Z, Li J, Baxter S, Callaway DJ, et al. (2010) A
conformational switch in the scaffolding protein NHERF1 controls autoinhibi-
tion and complex formation. J Biol Chem 285: 9981–9994.
12. Lau AG, Hall RA (2001) Oligomerization of NHERF-1 and NHERF-2 PDZ
domains: differential regulation by association with receptor carboxyl-termini
and by phosphorylation. Biochemistry 40: 8572–8580.
13. Fouassier L, Nichols MT, Gidey E, McWilliams RR, Robin H, et al. (2005)
Protein kinase C regulates the phosphorylation and oligomerization of ERM
binding phosphoprotein 50. Exp Cell Res 306: 264–273.
14. Hall RA, Spurney RF, Premont RT, Rahman N, Blitzer JT, et al. (1999) G
protein-coupled receptor kinase 6A phosphorylates the Na(+)/H(+) exchanger
regulatory factor via a PDZ domain-mediated interaction. J Biol Chem 274:
24328–24334.
15. He J, Lau AG, Yaffe MB, Hall RA (2001) Phosphorylation and cell cycle-
dependent regulation of Na+/H+ exchanger regulatory factor-1 by Cdc2 kinase.
J Biol Chem 276: 41559–41565.
16. Voltz JW, Brush M, Sikes S, Steplock D, Weinman EJ, et al. (2007)
Phosphorylation of PDZ1 domain attenuates NHERF-1 binding to cellular
targets. J Biol Chem 282: 33879–33887.
17. Garbett D, LaLonde DP, Bretscher A (2010) The scaffolding protein EBP50
regulates microvillar assembly in a phosphorylation-dependent manner. J Cell
Biol 191: 397–413.
18. Raghuram V, Hormuth H, Foskett JK (2003) A kinase-regulated mechanism
controls CFTR channel gating by disrupting bivalent PDZ domain interactions.
Proc Natl Acad Sci U S A 100: 9620–9625.
19. Csortos C, Kolosova I, Verin AD (2007) Regulation of vascular endothelial cell
barrier function and cytoskeleton structure by protein phosphatases of the PPP
family. Am J Physiol Lung Cell Mol Physiol 293: L843–854.
20. Keese CR, Wegener J, Walker SR, Giaever I (2004) Electrical wound-healing
assay for cells in vitro. Proc Natl Acad Sci U S A 101: 1554–1559.
21. Sharma GD, He J, Bazan HE (2003) p38 and ERK1/2 coordinate cellular
migration and proliferation in epithelial wound healing: evidence of cross-talk
activation between MAP kinase cascades. J Biol Chem 278: 21989–21997.
22. Wade JB, Welling PA, Donowitz M, Shenolikar S, Weinman EJ (2001)
Differential renal distribution of NHERF isoforms and their colocalization with
NHE3, ezrin, and ROMK. Am J Physiol Cell Physiol 280: C192–198.
Cell Cycle Dependent Association of EBP50 and PP2A
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35595
23. Hall RA, Ostedgaard LS, Premont RT, Blitzer JT, Rahman N, et al. (1998) A
C-terminal motif found in the beta2-adrenergic receptor, P2Y1 receptor and
cystic fibrosis transmembrane conductance regulator determines binding to the
Na+/H+ exchanger regulatory factor family of PDZ proteins. Proc Natl Acad
Sci U S A 95: 8496–8501.
24. Schmieder S, Nagai M, Orlando RA, Takeda T, Farquhar MG (2004)
Podocalyxin activates RhoA and induces actin reorganization through NHERF1
and Ezrin in MDCK cells. J Am Soc Nephrol 15: 2289–2298.
25. Weinman EJ, Hall RA, Friedman PA, Liu-Chen LY, Shenolikar S (2006) The
association of NHERF adaptor proteins with g protein-coupled receptors and
receptor tyrosine kinases. Annu Rev Physiol 68: 491–505.
26. Fouassier L, Rosenberg P, Mergey M, Saubamea B, Claperon A, et al. (2009)
Ezrin-radixin-moesin-binding phosphoprotein (EBP50), an estrogen-inducible
scaffold protein, contributes to biliary epithelial cell proliferation. Am J Pathol
174: 869–880.
27. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S (2003) EBP50, a
beta-catenin-associating protein, enhances Wnt signaling and is over-expressed
in hepatocellular carcinoma. Hepatology 38: 178–186.
28. Muranen T, Gronholm M, Renkema GH, Carpen O (2005) Cell cycle-
dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour
suppressor merlin. Oncogene 24: 1150–1158.
29. Batchelor CL, Woodward AM, Crouch DH (2004) Nuclear ERM (ezrin,
radixin, moesin) proteins: regulation by cell density and nuclear import. Exp Cell
Res 296: 208–222.
30. Kutay U, Hetzer MW (2008) Reorganization of the nuclear envelope during
open mitosis. Curr Opin Cell Biol 20: 669–677.
31. Nigg EA (1997) Nucleocytoplasmic transport: signals, mechanisms and
regulation. Nature 386: 779–787.
32. Baeyens N, de Meester C, Yerna X, Morel N (2011) EBP50 is involved in the
regulation of vascular smooth muscle cell migration and cytokinesis. J Cell
Biochem 112: 2574–2584.
33. Dai JL, Wang L, Sahin AA, Broemeling LD, Schutte M, et al. (2004) NHERF
(Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer.
Oncogene 23: 8681–8687.
34. Pan Y, Wang L, Dai JL (2006) Suppression of breast cancer cell growth by Na+/
H+ exchanger regulatory factor 1 (NHERF1). Breast Cancer Res 8: R63.
35. Wang S, Raab RW, Schatz PJ, Guggino WB, Li M (1998) Peptide binding
consensus of the NHE-RF-PDZ1 domain matches the C-terminal sequence of
cystic fibrosis transmembrane conductance regulator (CFTR). FEBS Lett 427:
103–108.
36. Schmitz MH, Held M, Janssens V, Hutchins JR, Hudecz O, et al. (2010) Live-
cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key
mitotic exit regulators in human cells. Nat Cell Biol 12: 886–893.
37. Wu JQ, Guo JY, Tang W, Yang CS, Freel CD, et al. (2009) PP1-mediated
dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1
and PP1 phosphorylation. Nat Cell Biol 11: 644–651.
38. Mochida S, Ikeo S, Gannon J, Hunt T (2009) Regulated activity of PP2A-B55
delta is crucial for controlling entry into and exit from mitosis in Xenopus egg
extracts. EMBO J 28: 2777–2785.
39. Hsu CC, Tsai WC, Chen CP, Lu YM, Wang JS (2010) Effects of negative
pressures on epithelial tight junctions and migration in wound healing.
Am J Physiol Cell Physiol 299: C528–534.
40. Vereb G, Matko J, Vamosi G, Ibrahim SM, Magyar E, et al. (2000) Cholesterol-
dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48
on T lymphoma cells suggest their functional association with lipid rafts. Proc
Natl Acad Sci U S A 97: 6013–6018.
Cell Cycle Dependent Association of EBP50 and PP2A
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35595
